← TENET HEALTHCARE CORP

Annual Trend FY 2016 FY 2017 FY 2018 FY 2019 FY 2020 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 TTM
Cash flows from operating activities:
Adjustments to reconcile net income to net cash provided by operating activities:
Net losses (gains) on sales, consolidation and deconsolidation of facilities — ($144.0m) ($127.0m) $15.0m ($14.0m) ($445.0m) — ($23.0m) ($2.9b) $1.0m —
Net Income (Loss) Available to Common Stockholders, Basic ($192.0m)
($704.0m) -266.67%
$111.0m +115.77%
($232.0m) -309.01%
$399.0m +271.98%
$914.0m +129.07%
$411.0m -55.03%
$611.0m +48.66%
$3.2b +423.73%
$1.4b -56.03%
—
Net Income (Loss) Attributable to Noncontrolling Interest $368.0m $384.0m $355.0m $386.0m $369.0m $562.0m $590.0m $700.0m $864.0m $960.0m —
Net Income (Loss), Including Portion Attributable to Noncontrolling Interest $176.0m ($320.0m) $466.0m $154.0m $768.0m $1.5b $1.0b $1.3b $4.1b $2.4b —
Amortization of Debt Issuance Costs and Discounts $41.0m $44.0m $45.0m $35.0m $38.0m $33.0m $33.0m $32.0m $26.0m $23.0m —
Amortization of Intangible Assets — $172.0m $185.0m $188.0m $172.0m $188.0m $172.0m $174.0m $172.0m $166.0m —
Amortization of debt discount and debt issuance costs $41.0m $44.0m $45.0m $35.0m $38.0m $33.0m $33.0m $32.0m $26.0m $23.0m —
Depreciation $850.0m $870.0m $802.0m $850.0m $857.0m $855.0m $669.0m $696.0m $646.0m $697.0m $697.0m
Depreciation, Depletion and Amortization $850.0m $870.0m $802.0m $850.0m $857.0m $855.0m $841.0m $870.0m $818.0m $863.0m $893.0m
Deferred Income Tax Expense (Benefit) $41.0m $200.0m $150.0m $137.0m ($128.0m) $250.0m $209.0m $52.0m ($103.0m) $9.0m $95.0m
Deferred Other Tax Expense (Benefit) $41.0m $200.0m $149.0m $133.0m ($127.0m) $250.0m $209.0m $52.0m ($103.0m) $9.0m —
Payment, Tax Withholding, Share-based Payment Arrangement — — — — — — — — — $51.0m —
Share-based Payment Arrangement, Expense — — $46.0m $42.0m $44.0m $56.0m $56.0m $66.0m $67.0m $104.0m $132.0m
Share-based Payment Arrangement, Noncash Expense $68.0m $59.0m $46.0m $42.0m $44.0m $56.0m $56.0m $66.0m $67.0m $104.0m $132.0m
Stock-based compensation expense $68.0m $59.0m $46.0m $42.0m $44.0m $56.0m $56.0m $66.0m $67.0m $104.0m $132.0m
Equity Method Investment, Other than Temporary Impairment — $31.0m — — — — — — — — —
Impairment and restructuring charges, and acquisition-related costs $202.0m $541.0m $209.0m $185.0m $290.0m $85.0m $226.0m $137.0m $102.0m $130.0m —
Income (Loss) from Equity Method Investments $131.0m $144.0m $150.0m $175.0m $169.0m $218.0m $216.0m $228.0m $260.0m $264.0m —
Other Nonoperating Income (Expense) — — — — $1.0m $14.0m $10.0m $19.0m $126.0m $117.0m —
Income (Loss) from Equity Method Investments, Net of Dividends or Distributions — $18 $12 $32 $37 $10 ($2) $13 $29 $34 —
Changes in operating assets and liabilities:
Accounts receivable ($1.6b) ($1.4b) ($134.0m) ($247.0m) $195.0m ($197.0m) ($140.0m) ($29.0m) $245.0m $20.0m ($53.0m)
Increase (Decrease) in Accounts Receivable $1.6b $1.4b $134.0m $247.0m ($195.0m) $197.0m $140.0m $29.0m ($245.0m) ($20.0m) ($53.0m)
Inventories and other current assets ($83.0m) ($35.0m) $17.0m ($94.0m) ($145.0m) ($52.0m) ($64.0m) ($139.0m) ($86.0m) ($73.0m) —
Accounts payable, accrued expenses and other current liabilities ($51.0m) ($10.0m) ($152.0m) $36.0m $1.3b ($584.0m) ($898.0m) $215.0m ($30.0m) $209.0m ($453.0m)
Proceeds from sales of facilities and other assets $573.0m $827.0m $543.0m $63.0m $77.0m $1.2b $210.0m $71.0m $5.0b $38.0m —
Net Cash Provided by (Used in) Operating Activities $558.0m
$1.2b +115.05%
$1.0b -12.58%
$1.2b +17.54%
$3.4b +176.32%
$1.6b -53.98%
$1.1b -30.93%
$2.4b +119.21%
$2.0b -13.77%
$3.5b +72.94%
$4.0b +13.42%
Cash flows from investing activities:
Payments to Acquire Property, Plant, and Equipment $875.0m $707.0m $617.0m $670.0m $540.0m $658.0m $762.0m $751.0m $931.0m $1.0b ($992.0m)
Gain (Loss) on Investments $8.0m — — — — — — — — — ($4.0m)
Net gains from the sale of investments and long-lived assets — — — — ($25.0m) ($23.0m) ($117.0m) ($29.0m) ($4.0m) ($4.0m) —
Payments to Acquire Investments — — — $62.0m $44.0m $108.0m $92.0m $104.0m $94.0m $90.0m ($129.0m)
Proceeds from sales of marketable securities and long-term investments $62.0m $36.0m $199.0m $82.0m $59.0m $31.0m $76.0m $50.0m $63.0m $93.0m —
Purchases of marketable securities and long-term investments — ($81.0m) ($148.0m) ($62.0m) ($44.0m) ($108.0m) ($92.0m) ($104.0m) ($94.0m) ($90.0m) —
Unrealized Gain (Loss) on Investments — — — — — — $1.0m — — — —
Payments to Acquire Businesses, Net of Cash Acquired $117.0m $50.0m $113.0m $25.0m $1.2b $1.2b $234.0m $224.0m $571.0m $308.0m ($291.0m)
Payments for (Proceeds from) Other Investing Activities $3.0m $7.0m $15.0m $0 ($18.0m) $7.0m $6.0m $11.0m $19.0m ($2.0m) —
Net Cash Provided by (Used in) Investing Activities ($430.0m) $21.0m ($115.0m) ($619.0m) ($1.6b) ($714.0m) ($808.0m) ($969.0m) $3.4b ($1.3b) ($1.3b)
Cash flows from financing activities:
Debt issuance costs ($12.0m) ($62.0m) $0 ($70.0m) ($48.0m) ($31.0m) ($24.0m) ($16.0m) $0 ($32.0m) —
Gain (Loss) on Extinguishment of Debt — ($164.0m) $1.0m ($227.0m) ($316.0m) ($74.0m) ($109.0m) ($11.0m) ($8.0m) ($4.0m) —
Loss from early extinguishment of debt $30.0m $164.0m ($1.0m) $227.0m $316.0m $74.0m $109.0m $11.0m $8.0m $4.0m —
Proceeds from borrowings — — — — — $2.9b $2.0b $1.4b $23.0m $2.3b —
Repayments of borrowings — — — — — ($3.2b) ($2.9b) ($1.5b) ($2.2b) ($2.4b) —
Payments for Repurchase of Common Stock — $0 — — — — $250.0m $200.0m $672.0m $1.4b —
Repurchases of common stock $0 $0 — — $0 $0 ($250.0m) ($200.0m) ($672.0m) ($1.4b) —
Proceeds from (Payments for) Other Financing Activities $16.0m $29.0m $54.0m $4.0m $10.0m ($64.0m) ($46.0m) $71.0m $33.0m $55.0m —
Net Cash Provided by (Used in) Financing Activities $232.0m
($1.3b) -671.55%
($1.1b) +14.48%
($763.0m) +32.72%
$385.0m +150.46%
($936.0m) -343.12%
($1.8b) -90.28%
($1.0b) +41.89%
($3.7b) -256.04%
($2.4b) +34.84%
($3.2b) -32.28%
Net increase (decrease) in cash and cash equivalents $360.0m ($105.0m) ($200.0m) ($149.0m) $2.2b ($82.0m) ($1.5b) $370.0m $1.8b ($136.0m) —
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect — — — ($149.0m) $2.2b ($82.0m) ($1.5b) $370.0m $1.8b ($136.0m) $2.2b
Cash and cash equivalents at beginning of period $356.0m $716.0m $611.0m $262.0m $2.4b $2.4b $858.0m $1.2b $3.0b $2.9b —
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents — — — $262.0m $2.4b $2.4b $858.0m $1.2b $3.0b $2.9b $2.2b
Additional Supplementary Disclosures
Additional Supplementary Disclosures
Additional Financial Items
Advances from managed care payers — — — — — — $0 $0 $342.0m $0 —
Equity in earnings of unconsolidated affiliates, net of distributions received ($13.0m) ($18.0m) ($12.0m) ($32.0m) ($37.0m) ($10.0m) $2.0m ($13.0m) ($29.0m) ($34.0m) —
Gain (Loss) Related to Litigation Settlement ($293.0m) ($23.0m) ($38.0m) ($141.0m) ($44.0m) ($116.0m) ($70.0m) ($47.0m) ($35.0m) ($64.0m) —
Gain (Loss) on Disposition of Assets — — — — — — $117.0m $29.0m $4.0m $4.0m —
Goodwill $7.4b $7.0b $7.3b $7.3b $8.8b $9.3b $10.1b $10.3b $10.7b $11.2b $73.0m
Income (Loss) from Continuing Operations, Net of Tax, Attributable to Parent ($187.0m) ($704.0m) $108.0m ($243.0m) $399.0m $915.0m $410.0m $611.0m $3.2b $1.4b —
Income (Loss) from Continuing Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest $181.0m ($320.0m) $463.0m $143.0m $768.0m $1.5b $1.0b $1.3b — — —
Income (Loss) from Discontinued Operations, Net of Tax, Attributable to Parent ($5.0m) $0 $3.0m $11.0m $0 ($1.0m) $1.0m $0 — — —
Income (Loss) from Discontinued Operations, Net of Tax, Including Portion Attributable to Noncontrolling Interest ($5.0m) $0 $3.0m $11.0m $0 ($1.0m) $1.0m $0 — — —
Income Tax Expense (Benefit) $67.0m $219.0m $176.0m $153.0m ($97.0m) $411.0m $344.0m $306.0m $1.2b $433.0m —
Income Taxes Paid, Net $33.0m $56.0m $25.0m $12.0m $12.0m $92.0m $161.0m $243.0m $1.3b $450.0m —
Income tax payments, net ($33.0m) ($56.0m) ($25.0m) ($12.0m) ($12.0m) ($92.0m) ($161.0m) ($243.0m) ($1.3b) ($450.0m) —
Income taxes ($8.0m) ($38.0m) ($3.0m) $8.0m $19.0m $68.0m ($26.0m) $10.0m $16.0m ($25.0m) —
Interest Expense Nonoperating — — — — — — — — $826.0m $821.0m —
Interest Paid, Excluding Capitalized Interest, Operating Activities $932.0m $939.0m $976.0m $946.0m $962.0m $937.0m $848.0m $882.0m $851.0m $865.0m —
Litigation and investigation costs $293.0m $23.0m $38.0m $141.0m $44.0m $116.0m $70.0m $47.0m $35.0m $64.0m —
Other items, net $16.0m $29.0m $54.0m $4.0m $10.0m ($64.0m) ($46.0m) $71.0m $33.0m $55.0m —
Other long-term liabilities $40.0m $26.0m ($102.0m) $3.0m $221.0m $28.0m ($15.0m) $14.0m ($9.0m) $9.0m —
Payments for restructuring charges, acquisition-related costs, and litigation costs and settlements ($691.0m) ($125.0m) ($163.0m) ($192.0m) ($333.0m) ($153.0m) ($214.0m) ($154.0m) ($153.0m) ($121.0m) —
Proceeds from Contributions from Affiliates — — — — $187.0m — — — — — —
Proceeds from Stock Options Exercised $4.0m — — — — — — — — — —
Proceeds from the sale of noncontrolling interests $22.0m $31.0m $20.0m $21.0m $14.0m $25.0m $27.0m $43.0m $23.0m $42.0m —
Purchases of businesses or joint venture interests, net of cash acquired ($117.0m) ($50.0m) ($113.0m) ($25.0m) ($1.2b) ($1.2b) ($234.0m) ($224.0m) ($571.0m) ($308.0m) —
Purchases of noncontrolling interests ($186.0m) ($729.0m) ($647.0m) ($11.0m) ($39.0m) ($27.0m) ($100.0m) ($167.0m) ($200.0m) ($92.0m) —
Repayments of advances from managed care payers — — — — — — $0 $0 ($310.0m) ($32.0m) —
Restructuring Costs — $117.0m $115.0m $137.0m $184.0m $57.0m $118.0m $79.0m $56.0m $44.0m —
Supplemental disclosure of cash flow information:

Amounts are shown in USD as reported in each fiscal year filing.

Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.